Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Amgen was incorporated in 1980 and is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics. Amgen opertates in one business segment, human therapeutics, and markets products in the areas of haematology, immunology, inflammation and oncology. Research and development efforts are focused on novel theraputics for the treatment of haematology, inflammation, oncology, metabolic disorders and neuroscience.

Amgen has established leadership positions with all of its principal products, attaining significant sales levels, and for most of its products, in a relatively short period of time. Such sales growth is unlikely to be maintained and increasing competition internationally will cause lower year-on-year sales increases. The first biosimilar products may be available in Europe and the in the anaemia area worldwide, shortly after the anticipated first approval in 2007.

Amgen believes that future sales growth for certain of its principal products should benefit from increased penetration and market growth through new areas of treatment and/or greater awareness. Further, over the last several years, the company's pipeline has substantially increased and with that comes the challenge of delivering on the pipeline, including executing on large and complex clinical trials.

For fiscal 2007, Amgen intends to balance short-term financial performance with significant R&D investment to drive long-term growth. The company plans to grow its markets and hold or increase share. Amgen will continue to vigorously defend its intellectual property and plans to take steps to grow its anaemia business. The company will continue to proactively manage and expand its production capacity ensuring that its commercial and clinical manufacturing is reliable and not subject to a single-point failure.

This new strategic analysis report Amgen: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.